Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Potential for enfortumab vedotin plus pembrolizumab in cisplatin-ineligible loca...
Prof Jonathan E Rosenberg - Memorial Sloan Kettering Cancer Center, New York Cit...
Potential for enfortumab vedotin plus pembrolizumab in cisplatin-ineligible locally advanced or metastatic urothelial cancer ( Prof Jonathan E Rosenberg - Memorial Sloan Kettering Cancer Center, New York City, USA )
14 Sep 2022
Pembrolizumab/carboplatin/paclitaxel combo shows antitumour activity in first-li...
Dr Marcin Dzienis - Gold Coast University Hospital, Southport, Australia
Pembrolizumab/carboplatin/paclitaxel combo shows antitumour activity in first-line recurrent/metastatic HNSCC ( Dr Marcin Dzienis - Gold Coast University Hospital, Southport, Australia )
14 Sep 2022
From clinic to practice in NSCLC patients with exon 20 mutations
Prof Nicolas Girard - Institut Curie, Paris, France
From clinic to practice in NSCLC patients with exon 20 mutations ( Prof Nicolas Girard - Institut Curie, Paris, France )
13 Sep 2022
ESMO 2022: Highlights, commentary and analysis
Dr Bishal Gyawali - Queen's University, Kingston, Canada
ESMO 2022: Highlights, commentary and analysis ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )
12 Sep 2022
Updates in prostate cancer from ESMO 2022
Prof Eleni Efstathiou, Prof Gerhardt Attard and Prof Boris Hadaschik
Updates in prostate cancer from ESMO 2022 ( Prof Eleni Efstathiou, Prof Gerhardt Attard and Prof Boris Hadaschik )
12 Sep 2022
Latest in mRCC from ESMO 2022
Dr Javier Puente, Dr Bernard Escudier, Prof Viktor Grünwald and Prof Stéphane Ou...
Latest in mRCC from ESMO 2022 ( Dr Javier Puente, Dr Bernard Escudier, Prof Viktor Grünwald and Prof Stéphane Oudard )
12 Sep 2022
Ideal duration of androgen deprivation therapy with post-operative radiotherapy ...
Prof Chris Parker - Institute of Cancer Research, Sutton, UK
Ideal duration of androgen deprivation therapy with post-operative radiotherapy for prostate cancer ( Prof Chris Parker - Institute of Cancer Research, Sutton, UK )
12 Sep 2022
Sotorasib shows superior PFS and ORR compared to docetaxel for NSCLC
Dr Silvia Novello - University of Turin, Turin, Italy
Sotorasib shows superior PFS and ORR compared to docetaxel for NSCLC ( Dr Silvia Novello - University of Turin, Turin, Italy )
12 Sep 2022
EGFR mutations in NSCLC - from biomarker to treatment selections in second line
Prof Nicolas Girard, Prof Keith Kerr, Dr Joshua Reuss and Dr Alfredo Addeo
EGFR mutations in NSCLC - from biomarker to treatment selections in second line ( Prof Nicolas Girard, Prof Keith Kerr, Dr Joshua Reuss and Dr Alfredo Addeo )
12 Sep 2022
Fruquintinib provides improvement in overall survival for refractory mCRC
Dr Nageshwara Arvind Dasari - MD Anderson Cancer Center, Houston, USA
Fruquintinib provides improvement in overall survival for refractory mCRC ( Dr Nageshwara Arvind Dasari - MD Anderson Cancer Center, Houston, USA )
12 Sep 2022
ESMO 2022: Breast cancer highlights
Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy
ESMO 2022: Breast cancer highlights ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )
12 Sep 2022
Sotorasib demonstrates superior PFS vs docetaxel for previously treated non-smal...
Dr Melissa Johnson - Sarah Cannon Research Institute, Nashville, USA
Sotorasib demonstrates superior PFS vs docetaxel for previously treated non-small cell lung cancer with KRAS G12C mutation ( Dr Melissa Johnson - Sarah Cannon Research Institute, Nashville, USA )
12 Sep 2022